{"success":true,"data":{"pressRelease":{"id":"155914","rtpr_id":"nGNX5njGRx-20260929","ticker":"LRMR","exchange":"NASDAQ","all_tickers":["LRMR"],"title":"Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer","author":"Globe Newswire","published_at":"2026-09-29T20:05:00.170Z","article_body":"BALA CYNWYD, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics,\nInc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused\non developing treatments for complex rare diseases, today announced the\nappointment of John Harlow as President and Chief Operating Officer, effective\nSeptember 29, 2026, reporting to Carole Ben-Maimon, M.D., Larimar’s Chief\nExecutive Officer. Mr. Harlow joins Larimar with more than 25 years of\ncommercial, operational and business development experience across the\nbiopharmaceutical industry.\n\n“As nomlabofusp advances toward potential approval, we are excited to\nwelcome John to our executive team,” said Carole Ben-Maimon, M.D., Chief\nExecutive Officer of Larimar. “His commercial and operational leadership,\ncoupled with his proven ability to translate strategy into execution, will be\ninstrumental as we scale the organization and prepare to bring nomlabofusp to\npatients worldwide.”\n\nMr. Harlow added, “Larimar has a unique opportunity to deliver the first\npotential disease-modifying therapy for adults and pediatric patients living\nwith Friedreich’s ataxia. I look forward to working with Carole and this\ntalented team to deliver a successful launch and position the company for\nlong-term growth.”\n\nMost recently, he served as Chief Commercial Officer of Esperion Therapeutics,\nwhere he led commercial operations, business development and global alliance\nmanagement. Previously, he served as Chief Commercial Officer of Melinta\nTherapeutics, where he built a robust commercial infrastructure with a\nhigh-performing team while achieving significant revenue growth and sustained\nprofitability ahead of its 2025 acquisition by CorMedix. Earlier in his\ncareer, Mr. Harlow held executive leadership roles at Baudax Bio, Recro Pharma\nand Endo Pharmaceuticals, as well as commercial and marketing leadership roles\nat Shionogi, Alpharma/King Pharmaceuticals, Novartis and Janssen. His earlier\nexperience also includes serving as an equity research analyst at Merrill\nLynch. Mr. Harlow holds an MBA in Pharmaceutical Management from Seton Hall\nUniversity and a BS in Biology from Lehigh University.\n\nInducement Grant Under Nasdaq Listing Rule 5635(c)(4)\n\nIn connection with Mr. Harlow’s appointment, the Compensation Committee of\nthe Board of Directors of the Company approved an inducement award, in\naccordance with Nasdaq Listing Rule 5635(c)(4), to Mr. Harlow, to be granted\non September 29, 2026 consisting of a (i) non-qualified stock option\n(“Option Award”) to purchase 800,000 shares of the Company’s common\nstock at an exercise price equal to the closing price per share of the\nCompany’s common stock as reported on the Nasdaq Global Market on the date\nof grant and (ii) restricted stock unit award in respect of 50,000 shares of\nthe Company’s common stock (“RSU Award” and together with the Option\nAward, the “Equity Awards”). The Equity Awards were granted as an\ninducement material to his acceptance of employment as President and Chief\nOperating Officer of the Company. The Option Award will vest over a four-year\nperiod, with 25% of the Option Award vesting on the first anniversary of the\ndate of grant, and the remaining 75% of the Option Award vesting in\nsubstantially equal monthly installments over thirty-six (36) months. The RSU\nAward will vest in four (4) substantially equal annual installments, beginning\non the first anniversary of the date of grant. The Equity Awards are subject\nto Mr. Harlow’s continued service with the Company through the applicable\nvesting dates and were granted outside the terms of the Company’s 2020\nEquity Incentive Plan.\n\nAbout Larimar Therapeutics\nLarimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology\ncompany focused on developing treatments for complex rare diseases.\nLarimar’s lead compound, nomlabofusp, is being developed as a potential\ntreatment for Friedreich's ataxia. Larimar also plans to use its intracellular\ndelivery platform to design other fusion proteins to target additional rare\ndiseases characterized by deficiencies in intracellular bioactive compounds.\nFor more information, please visit: https://larimartx.com.\n\nForward-Looking Statements\nThis press release contains forward-looking statements that are based on\nLarimar’s management’s beliefs and assumptions and on information\ncurrently available to management. All statements contained in this release\nother than statements of historical fact are forward-looking statements,\nincluding but not limited to statements regarding Larimar’s ability to\ndevelop and commercialize nomlabofusp and any other planned product\ncandidates, Larimar’s planned research and development efforts, including\nthe timing of its nomlabofusp clinical trials, dosing of the first patient in\na global confirmatory Phase 3 study, interactions and filings with the FDA,\nthe safety and therapeutic potential of nomlabofusp, expectations regarding\nthe timing of completion of the BLA submission, the expectations of the timing\nof, and potential for, accelerated approval or accelerated access, time to\nlaunch and market and overall development plans and other matters regarding\nLarimar’s business strategies, ability to raise capital, use of capital,\nresults of operations and financial position, and plans and objectives for\nfuture operations.\n\nIn some cases, you can identify forward-looking statements by the words\n“may,” “will,” “could,” “would,” “should,” “expect,”\n“intend,” “plan,” “anticipate,” “believe,” “estimate,”\n“predict,” “project,” “potential,” “continue,” “ongoing”\nor the negative of these terms or other comparable terminology, although not\nall forward-looking statements contain these words. These statements involve\nrisks, uncertainties and other factors that may cause actual results,\nperformance, or achievements to be materially different from the information\nexpressed or implied by these forward-looking statements. These risks,\nuncertainties and other factors include, among others, the success, cost and\ntiming of Larimar’s product development activities, nonclinical studies and\nclinical trials, including nomlabofusp clinical milestones and continued\ninteractions with the FDA; that preliminary clinical trial results may differ\nfrom final clinical trial results, that earlier non-clinical and clinical data\nand testing of nomlabofusp may not be predictive of the results or success of\nlater non-clinical or clinical trials, and assessments; delays in patient\nrecruitment, including as a result of changes in clinical protocols and\nadverse events; that the FDA may not ultimately agree with Larimar’s\nnomlabofusp development strategy; Larimar’s ability to submit BLA modules on\nthe intended timeline; Larimar’s ability to realize the benefits of\nBreakthrough Therapy Designation; the potential impact of public health crises\non Larimar’s future clinical trials, manufacturing, regulatory, nonclinical\nstudy timelines and operations, and general economic conditions; Larimar’s\nability and the ability of third-party manufacturers Larimar engages, to\noptimize and scale nomlabofusp’s manufacturing process; Larimar’s ability\nto obtain regulatory approvals for nomlabofusp and future product candidates;\nLarimar’s ability to develop sales and marketing capabilities, whether alone\nor with potential future collaborators, and to successfully commercialize any\napproved product candidates; Larimar’s ability to raise the necessary\ncapital to conduct its product development activities; and other risks\ndescribed in the filings made by Larimar with the Securities and Exchange\nCommission (SEC), including but not limited to Larimar’s periodic reports,\nincluding the annual report on Form 10-K, quarterly reports on Form 10-Q and\ncurrent reports on Form 8-K, filed with or furnished to the SEC and\navailable at www.sec.gov. These forward-looking statements are based on a\ncombination of facts and factors currently known by Larimar and its\nprojections of the future, about which it cannot be certain. As a result, the\nforward-looking statements may not prove to be accurate. The forward-looking\nstatements in this press release represent Larimar’s management’s views\nonly as of the date hereof. Larimar undertakes no obligation to update any\nforward-looking statements for any reason, except as required by law.\n\n Investor Contact: Joyce Allaire LifeSci Advisors jallaire@lifesciadvisors.com (212) 915-2569  Company Contact: Michael Celano Chief Financial Officer mcelano@larimartx.com (484) 414-2715  \n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/b02e1010-493d-4ec7-8523-c59602684d09)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX5njGRx-20260929","title":"Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer","author":"Globe Newswire","ticker":"LRMR","created":"2026-09-29T20:05:00.170Z","tickers":["LRMR"],"exchange":"NASDAQ","article_body":"BALA CYNWYD, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics,\nInc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused\non developing treatments for complex rare diseases, today announced the\nappointment of John Harlow as President and Chief Operating Officer, effective\nSeptember 29, 2026, reporting to Carole Ben-Maimon, M.D., Larimar’s Chief\nExecutive Officer. Mr. Harlow joins Larimar with more than 25 years of\ncommercial, operational and business development experience across the\nbiopharmaceutical industry.\n\n“As nomlabofusp advances toward potential approval, we are excited to\nwelcome John to our executive team,” said Carole Ben-Maimon, M.D., Chief\nExecutive Officer of Larimar. “His commercial and operational leadership,\ncoupled with his proven ability to translate strategy into execution, will be\ninstrumental as we scale the organization and prepare to bring nomlabofusp to\npatients worldwide.”\n\nMr. Harlow added, “Larimar has a unique opportunity to deliver the first\npotential disease-modifying therapy for adults and pediatric patients living\nwith Friedreich’s ataxia. I look forward to working with Carole and this\ntalented team to deliver a successful launch and position the company for\nlong-term growth.”\n\nMost recently, he served as Chief Commercial Officer of Esperion Therapeutics,\nwhere he led commercial operations, business development and global alliance\nmanagement. Previously, he served as Chief Commercial Officer of Melinta\nTherapeutics, where he built a robust commercial infrastructure with a\nhigh-performing team while achieving significant revenue growth and sustained\nprofitability ahead of its 2025 acquisition by CorMedix. Earlier in his\ncareer, Mr. Harlow held executive leadership roles at Baudax Bio, Recro Pharma\nand Endo Pharmaceuticals, as well as commercial and marketing leadership roles\nat Shionogi, Alpharma/King Pharmaceuticals, Novartis and Janssen. His earlier\nexperience also includes serving as an equity research analyst at Merrill\nLynch. Mr. Harlow holds an MBA in Pharmaceutical Management from Seton Hall\nUniversity and a BS in Biology from Lehigh University.\n\nInducement Grant Under Nasdaq Listing Rule 5635(c)(4)\n\nIn connection with Mr. Harlow’s appointment, the Compensation Committee of\nthe Board of Directors of the Company approved an inducement award, in\naccordance with Nasdaq Listing Rule 5635(c)(4), to Mr. Harlow, to be granted\non September 29, 2026 consisting of a (i) non-qualified stock option\n(“Option Award”) to purchase 800,000 shares of the Company’s common\nstock at an exercise price equal to the closing price per share of the\nCompany’s common stock as reported on the Nasdaq Global Market on the date\nof grant and (ii) restricted stock unit award in respect of 50,000 shares of\nthe Company’s common stock (“RSU Award” and together with the Option\nAward, the “Equity Awards”). The Equity Awards were granted as an\ninducement material to his acceptance of employment as President and Chief\nOperating Officer of the Company. The Option Award will vest over a four-year\nperiod, with 25% of the Option Award vesting on the first anniversary of the\ndate of grant, and the remaining 75% of the Option Award vesting in\nsubstantially equal monthly installments over thirty-six (36) months. The RSU\nAward will vest in four (4) substantially equal annual installments, beginning\non the first anniversary of the date of grant. The Equity Awards are subject\nto Mr. Harlow’s continued service with the Company through the applicable\nvesting dates and were granted outside the terms of the Company’s 2020\nEquity Incentive Plan.\n\nAbout Larimar Therapeutics\nLarimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology\ncompany focused on developing treatments for complex rare diseases.\nLarimar’s lead compound, nomlabofusp, is being developed as a potential\ntreatment for Friedreich's ataxia. Larimar also plans to use its intracellular\ndelivery platform to design other fusion proteins to target additional rare\ndiseases characterized by deficiencies in intracellular bioactive compounds.\nFor more information, please visit: https://larimartx.com.\n\nForward-Looking Statements\nThis press release contains forward-looking statements that are based on\nLarimar’s management’s beliefs and assumptions and on information\ncurrently available to management. All statements contained in this release\nother than statements of historical fact are forward-looking statements,\nincluding but not limited to statements regarding Larimar’s ability to\ndevelop and commercialize nomlabofusp and any other planned product\ncandidates, Larimar’s planned research and development efforts, including\nthe timing of its nomlabofusp clinical trials, dosing of the first patient in\na global confirmatory Phase 3 study, interactions and filings with the FDA,\nthe safety and therapeutic potential of nomlabofusp, expectations regarding\nthe timing of completion of the BLA submission, the expectations of the timing\nof, and potential for, accelerated approval or accelerated access, time to\nlaunch and market and overall development plans and other matters regarding\nLarimar’s business strategies, ability to raise capital, use of capital,\nresults of operations and financial position, and plans and objectives for\nfuture operations.\n\nIn some cases, you can identify forward-looking statements by the words\n“may,” “will,” “could,” “would,” “should,” “expect,”\n“intend,” “plan,” “anticipate,” “believe,” “estimate,”\n“predict,” “project,” “potential,” “continue,” “ongoing”\nor the negative of these terms or other comparable terminology, although not\nall forward-looking statements contain these words. These statements involve\nrisks, uncertainties and other factors that may cause actual results,\nperformance, or achievements to be materially different from the information\nexpressed or implied by these forward-looking statements. These risks,\nuncertainties and other factors include, among others, the success, cost and\ntiming of Larimar’s product development activities, nonclinical studies and\nclinical trials, including nomlabofusp clinical milestones and continued\ninteractions with the FDA; that preliminary clinical trial results may differ\nfrom final clinical trial results, that earlier non-clinical and clinical data\nand testing of nomlabofusp may not be predictive of the results or success of\nlater non-clinical or clinical trials, and assessments; delays in patient\nrecruitment, including as a result of changes in clinical protocols and\nadverse events; that the FDA may not ultimately agree with Larimar’s\nnomlabofusp development strategy; Larimar’s ability to submit BLA modules on\nthe intended timeline; Larimar’s ability to realize the benefits of\nBreakthrough Therapy Designation; the potential impact of public health crises\non Larimar’s future clinical trials, manufacturing, regulatory, nonclinical\nstudy timelines and operations, and general economic conditions; Larimar’s\nability and the ability of third-party manufacturers Larimar engages, to\noptimize and scale nomlabofusp’s manufacturing process; Larimar’s ability\nto obtain regulatory approvals for nomlabofusp and future product candidates;\nLarimar’s ability to develop sales and marketing capabilities, whether alone\nor with potential future collaborators, and to successfully commercialize any\napproved product candidates; Larimar’s ability to raise the necessary\ncapital to conduct its product development activities; and other risks\ndescribed in the filings made by Larimar with the Securities and Exchange\nCommission (SEC), including but not limited to Larimar’s periodic reports,\nincluding the annual report on Form 10-K, quarterly reports on Form 10-Q and\ncurrent reports on Form 8-K, filed with or furnished to the SEC and\navailable at www.sec.gov. These forward-looking statements are based on a\ncombination of facts and factors currently known by Larimar and its\nprojections of the future, about which it cannot be certain. As a result, the\nforward-looking statements may not prove to be accurate. The forward-looking\nstatements in this press release represent Larimar’s management’s views\nonly as of the date hereof. Larimar undertakes no obligation to update any\nforward-looking statements for any reason, except as required by law.\n\n Investor Contact: Joyce Allaire LifeSci Advisors jallaire@lifesciadvisors.com (212) 915-2569  Company Contact: Michael Celano Chief Financial Officer mcelano@larimartx.com (484) 414-2715  \n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/b02e1010-493d-4ec7-8523-c59602684d09)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-29T20:05:00.205643795Z","server_sent_at_ms":1790712300205},"received_at":"2026-09-29T20:05:00.322Z","source_url":null},"analysis":{"id":"144634","press_release_id":"155914","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"executive_change","narrative":"Larimar Therapeutics appointed John Harlow as President and Chief Operating Officer, effective September 29, 2026, reporting to CEO Carole Ben-Maimon.\n\nHarlow brings more than 25 years of biopharma commercial and operational experience, most recently as Chief Commercial Officer of Esperion, with prior roles at Melinta, Baudax Bio, Recro Pharma, Endo, Novartis and Janssen.\n\nThe hire signals launch-readiness for nomlabofusp, Larimar's lead candidate for Friedreich's ataxia, as the company nears potential accelerated approval and prepares to scale commercially.\n\nIn connection with the appointment, Harlow received Nasdaq Rule 5635(c)(4) inducement awards: options on 800,000 shares vesting over four years and RSUs on 50,000 shares vesting annually over four years.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Commercial-launch veteran COO hire signals Larimar is staffing up ahead of a potential nomlabofusp approval."},"keyFigures":{"customDimensions":{"inducement_rsu_shares":50000,"inducement_option_shares":800000}},"quotedText":"His commercial and operational leadership, coupled with his proven ability to translate strategy into execution, will be instrumental as we scale the organization and prepare to bring nomlabofusp to patients worldwide.","namedEntities":{"people":[{"name":"John Harlow","role":"President and Chief Operating Officer (new appointee)"},{"name":"Carole Ben-Maimon, M.D.","role":"CEO"},{"name":"Michael Celano","role":"Chief Financial Officer"}],"products":["nomlabofusp"],"companies":[{"name":"Larimar Therapeutics, Inc.","ticker":"LRMR"},{"name":"Esperion Therapeutics","relationship":"Harlow's prior employer"},{"name":"Melinta Therapeutics","relationship":"Harlow's prior employer"},{"name":"CorMedix","relationship":"acquirer of Melinta"},{"name":"Baudax Bio","relationship":"Harlow's prior employer"},{"name":"Recro Pharma","relationship":"Harlow's prior employer"},{"name":"Endo Pharmaceuticals","relationship":"Harlow's prior employer"},{"name":"Novartis","relationship":"Harlow's prior employer"},{"name":"Janssen","relationship":"Harlow's prior employer"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Appointment of a President/COO with commercial launch experience as nomlabofusp nears potential approval. It is an addition rather than a departure, and no CEO/CFO change occurred, so impact is modest but constructive."},"tickerRelevance":{"others":[],"primary":"LRMR"},"globalImportance":22,"audienceRelevance":18,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap clinical-stage biotech","eventGravity":"executive_hire_not_departure","launchReadinessSignal":true}},"event_type":"executive_change","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Larimar Therapeutics appointed John Harlow as President and Chief Operating Officer, effective September 29, 2026, reporting to CEO Carole Ben-Maimon.\n\nHarlow brings more than 25 years of biopharma commercial and operational experience, most recently as Chief Commercial Officer of Esperion, with prior roles at Melinta, Baudax Bio, Recro Pharma, Endo, Novartis and Janssen.\n\nThe hire signals launch-readiness for nomlabofusp, Larimar's lead candidate for Friedreich's ataxia, as the company nears potential accelerated approval and prepares to scale commercially.\n\nIn connection with the appointment, Harlow received Nasdaq Rule 5635(c)(4) inducement awards: options on 800,000 shares vesting over four years and RSUs on 50,000 shares vesting annually over four years.","key_figures":{"customDimensions":{"inducement_rsu_shares":50000,"inducement_option_shares":800000}},"named_entities":{"people":[{"name":"John Harlow","role":"President and Chief Operating Officer (new appointee)"},{"name":"Carole Ben-Maimon, M.D.","role":"CEO"},{"name":"Michael Celano","role":"Chief Financial Officer"}],"products":["nomlabofusp"],"companies":[{"name":"Larimar Therapeutics, Inc.","ticker":"LRMR"},{"name":"Esperion Therapeutics","relationship":"Harlow's prior employer"},{"name":"Melinta Therapeutics","relationship":"Harlow's prior employer"},{"name":"CorMedix","relationship":"acquirer of Melinta"},{"name":"Baudax Bio","relationship":"Harlow's prior employer"},{"name":"Recro Pharma","relationship":"Harlow's prior employer"},{"name":"Endo Pharmaceuticals","relationship":"Harlow's prior employer"},{"name":"Novartis","relationship":"Harlow's prior employer"},{"name":"Janssen","relationship":"Harlow's prior employer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-29T20:05:05.842Z","global_importance":22,"audience_relevance":18,"importance_components":{"tickerTier":"small-cap clinical-stage biotech","eventGravity":"executive_hire_not_departure","launchReadinessSignal":true}},"durationMs":5483,"modelName":"glm-5.3-flashx"}}